Teva-JPM-20240108 .pdf

《Teva-JPM-20240108 .pdf》由会员分享，可在线阅读，更多相关《Teva-JPM-20240108 .pdf（18页珍藏版）》请在三个皮匠报告上搜索。

1、Teva Pharmaceutical Industries Ltd.4242ndnd Annual Annual J.P.Morgan Healthcare J.P.Morgan Healthcare ConferenceConferenceJanuary 8,20242|This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on managements cu

2、rrent beliefs and expectations and are subject to substantial risks and uncertainties,both known and unknown,that could cause our future results,performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.Important factors that could cause or

3、 contribute to such differences include risks relating to:our ability to successfully compete in the marketplace,including:that we are substantially dependent on our generic products;concentration of our customer base and commercial alliances among our customers;delays in launches of new generic pro

4、ducts;the increase in the number of competitors targeting generic opportunities and seeking U.S.market exclusivity for generic versions of significant products;our ability to develop and commercialize biopharmaceutical products;competition for our innovative medicines;our ability to achieve expected

5、 results from investments in our product pipeline;our ability to develop and commercialize additional pharmaceutical products;our ability to successfully launch and execute our new Pivot to Growth strategy,including to expand our innovative and biosimilar medicines pipeline and profitably commercial

6、ize the innovative medicines and biosimilar portfolio,whether organically or through business development,and to sustain and focus our portfolio of generics medicines;and the effectiveness of our patents and other measures to protect our intellectual property rights,including any potential challenge